melanotan 2 dosage: Frequently asked questions

Calculate total available doses by dividing vial mass by target dose per administration. A 10mg vial provides 10 ÷ 0.5 = 20 doses at 0.5mg each, or 40 doses at 0.25mg each. After reconstitution, each dose is the same injection volume. 0.1mL per 0.5mg dose if reconstituted to 5mg/mL. Mark each withdrawal on the vial label to track remaining doses. Reconstituted Melanotan-2 stored at 2–8°C in bacteriostatic water remains stable for 28 days, so a 10mg vial providing 20 doses administered every other day fits well within the stability window.

Round your calculated dose to the nearest whole unit that your syringe can measure. If your calculation yields 7.5 units but your syringe only has 1-unit graduations, you must choose either 7 or 8 units. There's no way to measure 7.5 accurately. For protocols requiring sub-unit precision, either reconstitute at a lower concentration (so doses land on whole units) or use a syringe with 0.5-unit markings. Most U-100 insulin syringes mark every 1 unit; specialty low-dose syringes (0.3mL or 0.5mL total capacity) often include half-unit graduations.

Recalculate concentration using the actual volume added. If you intended 2mL but accidentally added 2.3mL to a 10mg vial, your concentration is now 10 ÷ 2.3 = 4.35mg/mL instead of 5mg/mL. Adjust your injection volume accordingly: a 0.5mg dose now requires 0.5 ÷ 4.35 = 0.115mL (11.5 units) instead of 10 units. The peptide isn't ruined. You just need to draw slightly more volume per dose. Write the corrected concentration on the vial label to avoid confusion on subsequent administrations.

Yes, but only if the change exceeds 5kg or 7% of starting body weight. Melanocortin receptor distribution scales with body surface area, which changes meaningfully only with significant weight fluctuation. A 75kg researcher who gains 2kg doesn't need to recalculate. The receptor saturation difference is negligible. A 75kg researcher who gains 8kg should recalculate using the new weight: 83kg × 0.015mg/kg = 1.25mg vs 1.13mg originally. That 0.12mg difference (roughly 10%) can shift you from under-saturated to optimal MC1R activation. Weight loss follows the same rule. Recalculate if the change is substantial, ignore minor fluctuations.

Calculate two separate doses: a loading dose for weeks 1–4 (daily administration at 0.01–0.02mg/kg) and a maintenance dose for weeks 5–12 (2–3x weekly at 50–70% of loading dose). If your loading dose is 1mg daily, your maintenance dose is 0.5–0.7mg administered every 2–3 days. Mark your calendar with exact dosing days. Melanocortin receptor sensitivity degrades quickly with inconsistent dosing, and you'll lose the cumulative melanogenic response you built during loading phase. Researchers who switch to maintenance dosing without reducing milligram amount experience side effect resurgence because intermittent high-dose administration hits desensitized receptors at full strength.

Discard the vial immediately and do not inject cloudy solution. Cloudiness indicates either bacterial contamination (if bacteriostatic water was compromised), protein aggregation (if the peptide was exposed to heat or freeze-thaw cycles), or incomplete dissolution (if you added water too aggressively). Melanotan-2 should dissolve into a clear, colorless solution within 60–90 seconds of gentle swirling. Never shake the vial, as mechanical agitation denatures the peptide. If your reconstitution produces cloudiness consistently, the issue is either peptide quality (aggregated protein from poor storage pre-sale) or water contamination. Real Peptides' lyophilised peptides dissolve cleanly because small-batch synthesis minimizes protein aggregation during freeze-drying.

Reduce your dose by 50% immediately and hold at that level for 4–5 days before attempting to increase again. Severe nausea lasting more than 2 hours post-injection indicates MC4R overstimulation in the hypothalamus, which means your dose exceeded your current receptor desensitization threshold. Titration isn't optional. Even if your body-weight calculation suggests 1mg, your receptors may require 3–4 weeks of gradual escalation to tolerate that dose. Anti-nausea medications like ondansetron can mask the symptom but don't address receptor saturation. You're better off re-calibrating dose than medicating through side effects.

Discard the vial. Temperature excursion above 8°C for more than 6–8 hours causes methionine oxidation that reduces receptor binding affinity by 15–40%, but visual inspection cannot detect this degradation. The solution remains clear and colourless even when bioactivity is compromised. Using partially degraded peptide doesn't create safety risk, but it delivers unpredictable dosing that invalidates research protocols requiring consistent plasma concentration.

Do not use it. Cloudiness indicates either bacterial contamination (if stored beyond 30 days or reconstituted with non-bacteriostatic water) or protein aggregation (if the lyophilised powder was exposed to moisture before reconstitution). Particulates visible to the naked eye suggest stopper degradation or peptide precipitation. Both require immediate disposal.

Reduce the next dose by 50% and extend the titration schedule by 3–5 days. Nausea results from MC4R activation in the hypothalamus and typically resolves within 48–72 hours as receptor downregulation occurs, but some subjects require slower titration to allow receptor adaptation. Administering doses with food (rather than fasted) and timing injections for evening (rather than morning) both reduce nausea severity without affecting endpoint efficacy.

Increase maintenance frequency from twice weekly to three times weekly (e.g., Monday, Wednesday, Friday) or increase the dose from 0.5mg to 1mg per injection. Melanin turnover rates vary by individual: skin cell turnover (keratinocyte shedding) occurs every 28–40 days, and melanosomes are degraded by autophagy within melanocytes over similar timeframes. Some users require 1mg three times weekly to maintain peak pigmentation, particularly during winter months with minimal UV exposure. Adjust based on visual assessment. If pigmentation noticeably fades within 5–7 days of your last injection, your current maintenance dose is insufficient.

No. Pigmentation fades gradually over 4–8 weeks after the final injection as melanosomes are degraded and keratinocytes turn over. You will not 'turn pale overnight.' If you want to accelerate fading, avoid UV exposure and use topical agents that inhibit tyrosinase (kojic acid, arbutin, niacinamide). Though these have modest efficacy. Most users who stop MT2 report returning to baseline skin tone within 12–16 weeks without intervention.

Reduce your next dose to 0.25mg and remain at that dose for 5–7 days before attempting 0.5mg again. Severe nausea indicates MC4R oversaturation. Your receptor density has not yet adapted to the dose. Taking an antiemetic (ondansetron 4mg, prochlorperazine 5mg) 30 minutes before injection can mitigate symptoms during titration, but dose reduction is the definitive solution. Nausea that persists beyond 4–6 hours post-injection or triggers vomiting suggests the dose is too high for your current tolerance. Do not push through severe nausea hoping it will resolve. MC4R desensitization takes 7–14 days of consistent exposure at a tolerable dose, not a single high-dose injection.

If you miss a dose during the loading phase by fewer than 24 hours, administer the missed dose as soon as you remember and continue your regular schedule. If more than 24 hours have passed, skip the missed dose and resume on your next scheduled day. Do not double-dose to 'catch up.' Melanogenesis is cumulative: missing one dose delays visible pigmentation by 1–2 days but does not reset progress. Missing 3+ consecutive days during loading may require extending the loading phase by 3–5 additional days to reach target pigmentation.

MT2 will produce pigmentation without UV, but expect a longer timeline (6–8 weeks vs 3–4 weeks) and less uniform tan distribution. The peptide stimulates melanogenesis, but without UV-induced melanin oxidation, the tan appears lighter and more yellowish-brown than the deep brown achieved with UV synergy. Some users prefer this approach to avoid UV-related skin aging, accepting the trade-off in tan depth.

Resume at the dose you were using before the missed day. Do not double-dose to 'catch up.' Loading phases establish receptor priming gradually; a single missed day does not reset progress. If you miss 3+ consecutive days, restart the loading phase from 0.25mg to re-establish receptor adaptation without triggering acute nausea from a higher dose after a gap.

Daily low-dose protocols (0.5mg or less) sustained over weeks to months produce cumulative melanocortin receptor effects, including baseline libido elevation and increased spontaneous sexual ideation. But they also accelerate skin pigmentation, which becomes permanent with prolonged use. No long-term safety data exists for MT-2 beyond 16 weeks of continuous administration in clinical trials. Cycling protocols (e.g., 4 weeks on, 2 weeks off) are commonly used in research settings to mitigate cumulative side effects, though the optimal cycle length for libido maintenance has not been formally studied.

This indicates melanocortin receptor downregulation from chronic stimulation. Discontinue MT-2 for 2–4 weeks to allow receptor density to normalise, then resume at a lower frequency (2×/week maximum instead of daily or every-other-day). Chronic daily dosing is the primary driver of tolerance development. Intermittent protocols maintain sensitivity indefinitely in most cases.

Reduce to 0.25mg daily and extend the loading phase to 14–21 days. Nausea severity correlates with dose escalation speed. Slower titration allows MC4R desensitization, reducing gastrointestinal distress. Take the injection with food and avoid dosing within three hours of vigorous physical activity, which amplifies nausea through increased gut motility. If nausea persists beyond one week at 0.25mg, Melanotan-2 may not be tolerable at any therapeutic dose.

Administer MT-2 on an empty stomach or with a small protein-based snack (not high-fat meals, which delay absorption) and consider splitting the daily dose into two smaller injections 8–12 hours apart to reduce peak plasma concentration. Nausea is MC4R-mediated and dose-dependent. If it persists beyond the first week of consistent dosing, reduce your dose by 25–50%. Ginger supplementation (1g) taken 30 minutes before injection reduces nausea severity in approximately 40% of users based on small observational studies, though this is not a substitute for dose reduction if symptoms are severe.